Reducing infectious malaria parasites in donated blood could help prevent transmission

April 21, 2016, University of Cambridge
Credit: CDC

A technique for reducing the number of infectious malaria parasites in whole blood could significantly reduce the number of cases of transmission of malaria through blood transfusion, according to a collaboration between researchers in Cambridge, UK, and Kumasi, Ghana.

Malaria is a blood-borne disease caused by the parasite - in west Africa, this is mainly Plasmodium falciparum. The parasite is mainly transmitted to humans through . In sub-Saharan Africa, is endemic and a substantial proportion of the population carries the parasite, even when individuals do not show any symptoms. Only a few blood centres screen donor blood of the parasite and hence there is a high risk of through transfusion.

Because of resource limitations, the most common red blood cell product transfused is whole blood. A half of all in Ghana carry detectable levels of malaria parasites in the blood and as many as one in four (between 14-28%) of blood recipients become infected.

The Mirasol pathogen reduction technology system, developed by the US-based Japanese company Terumo BCT, has been developed to treat whole blood using ultraviolet light energy and riboflavin (vitamin B2) to reduce the parasite load and to inactivate white blood cells. It has been shown to reduce P. falciparum load in vitro and to maintain adequate blood quality during 21 days of cold storage.

In a study published today in The Lancet and funded by Terumo BCT, researchers report the results of the African Investigation of the Mirasol System (AIMS) trial, which explored whether the use of blood treated with Mirasol would prevent the transmission of malaria to patients with anaemia being supported with whole blood transfusion.

"In developing countries, blood supplies are often contaminated and blood banking systems cannot afford the newest technologies for detecting blood-borne pathogens," explains Professor Jean-Pierre Allain from the Department of Haematology at the University of Cambridge. "Technologies aimed at reducing the levels of parasites or infectious agents in the blood could benefit individual patients and also health-care systems."

The trial involved 214 patients, 107 of whom received Mirasol-treated blood, the remainder of whom received the normal blood products. Overall, 65 patients who previously were free of detectable parasites were transfused with blood retrospectively found to contain parasites - 28 of these blood products had been treated with Mirasol, 37 were untreated.

The incidence of transfusion-transmitted malaria was significantly lower for those patients who received the treated blood (one out of 28 patients, or 4%) compared to the untreated group (eight out of 37 patients, or 22%).

At the same time, the safety profile did not differ for patients receiving treated or untreated whole blood units. The treated whole blood group had fewer allergic reactions to the transfusion (5% vs 8%) and fewer overall reactions (8% vs 13%), possibly because of the technology also inactivates white blood cells including immune cells.

The researchers recognise that the overall number of transmissions was small, reducing the power of the study, but believe it still provides a clear indication that the Mirasol system could make a dramatic difference to the number of cases of malaria transmission via .

"This could be a real game-changer for blood safety in sub-Saharan African," adds Dr Shirley Owusu-Ofori from the Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana. "Reduced transfusion-transmissions of infectious agents means a more stable supply, reduced costs for the treatment of preventable infections, and direct benefits to women and children who are especially vulnerable to malaria."

Explore further: Cracking the code of the malaria parasite may help stop transmission

More information: Allain, JP et al. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet; 23 April 2016.

Related Stories

Cracking the code of the malaria parasite may help stop transmission

April 15, 2016
The most dangerous malaria parasite, Plasmodium falciparum, is responsible for nearly half a million deaths annually across Africa and Southeast Asia. Of increasing concern, this parasite is now developing resistance to common ...

Shorter times to blood transfusion associated with decreased death risk in trauma patients

April 14, 2016
Patients who get blood quickly after severe injuries are less likely to die, according to researchers from the University of Cincinnati (UC) Department of Emergency Medicine.

Potential pathway for emergence of zoonotic malaria identified

April 4, 2016
The parasite responsible for a form of malaria now spreading from macaques to humans in South Asia could evolve to infect humans more efficiently, a step towards enhanced transmission between humans, according to a new study ...

Malaria parasite's essential doorway into red blood cells illuminated

May 7, 2015
Researchers at Harvard T. H. Chan School of Public Health and the Broad Institute have identified a protein on the surface of human red blood cells that serves as an essential entry point for invasion by the malaria parasite. ...

Recommended for you

Experimental vaccine shows promise in preventing TB

September 25, 2018
(HealthDay)—Tuberculosis remains the most lethal of infectious diseases worldwide, killing more than 1.6 million people a year. But researchers say a new vaccine might prevent half of full-blown illnesses in infected people ...

Researchers seek vaccine for 'traveler's diarrhea'

September 25, 2018
Every year, millions of people have vacations and business trips ruined when they succumb to "traveler's diarrhea" during their journeys. A major cause of traveler's diarrhea is bacteria called Enterotoxigenic E. coli, or ...

Many doctors in India miss TB signs: study

September 25, 2018
Many private sector doctors in India miss the signs of tuberculosis and therefore provide patients inadequate treatment, according to a new study published Tuesday involving people hired to act out the symptoms.

New way of determining treatment for staph infections cuts antibiotic use

September 25, 2018
Using a clinical checklist to identify eligible patients, doctors were able to shorten the antibiotic duration for patients with uncomplicated staphylococcal bloodstream infections by nearly two days, Duke Health researchers ...

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.